Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Zenara Pharma to market generic version of Paxlovid in India

By Brian Buntz | September 12, 2022

ZenaraHyderabad, India–based Zenara Pharma has launched a generic version of Pfizer’s (NYSE:PFE) COVID-19 antiviral Paxlovid (nirmatrelvir and ritonavir).

Zenara Pharma is naming the generic version of the pill “Paxzen.”

The antiviral is indicated for mild to moderate symptoms of COVID-19.

India’s Central Drugs Standard Control Organisation (CDSCO) cleared the way for authorization of the drug in the country by approving the generic antiviral last month.

FDA authorized Paxlovid in December 2021. Pfizer signaled its intent to seek full approval of the drug in late June.

Zenara Pharma will manufacture its version of the drug at an FDA- and EU-approved facility in Hyderabad.

The company plans to sell the drug at a maximum retail price of 5,200 rupees per box. One box contains 20 tablets (150 ml) of nirmatrelvir and 10 tablets of ritonavir (100 mg).

“We have launched this product in India with an aim to bring the best treatment options against COVID within reach of patients in our country,” said Jagadeesh Babu Rangisetty, co-founder and managing director at Zenara Pharma, in a news release. “Our product, Paxzen, has been proven equivalent to Paxlovid through a bioequivalence study, based on which we have received the approval from the regulatory authorities.

Zenara Pharma is a subsidiary of Biophore India Pharmaceuticals.

The analyst firm GlobalData team anticipates that Paxlovid will generate $81 billion in revenue from 2021 to 2028.

Pfizer expects the drug to have sales of $22 billion in 2022.

The initial use of the drug was limited to individuals with an elevated risk of severe COVID-19. The company notes that 40-50% of people globally are likely to face a high risk of contracting severe COVID-19.

The WHO recommended Paxlovid for people with a mild or moderate COVID-19 illness with an elevated risk of hospitalization.

Paxlovid has found more widespread use than Merck’s COVID-19 antiviral molnupiravir.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Comments

  1. Dr.K.P.Gopinathan says

    October 13, 2022 at 4:50 am

    What is the current cost of the drug PAXAZE in India and are they marketd as single tablets?

    Reply
  2. Dr.K.P.Gopinathan says

    October 13, 2022 at 4:54 am

    Give the information soon please

    Reply

Tell Us What You Think! Cancel reply

Related Articles Read More >

institut pasteur dakar IPD African Union vaccine investment
African Union vaccine initiative receives $45M
Sen-Jam Pharma, KVK-Tech partnering for manufacturing and formulation for anti-inflammatory injectables
This image shows the Moderna logo.
Moderna resizes its manufacturing footprint for a post-pandemic era
This is the logo of Pfizer.
Pfizer to close Durham and Morrisville, North Carolina facilities amid major restructuring effort
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE